Cargando…
Ceftriaxone-induced Encephalopathy: A Pharmacokinetic Approach
We report a case of ceftriaxone-induced encephalopathy correlated with a high concentration of the drug in cerebrospinal fluid (CSF). Cephalosporin neurotoxicity is increasingly reported, especially in association with fourth-generation cephalosporins. The factors influencing CSF concentration are p...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SMC Media Srl
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8667992/ https://www.ncbi.nlm.nih.gov/pubmed/34912745 http://dx.doi.org/10.12890/2021_003011 |
_version_ | 1784614476942671872 |
---|---|
author | Jadot, Laurent Judong, Aurelie Canivet, Jean-Luc Lorenzo-Villalba, Noel Damas, Pierre |
author_facet | Jadot, Laurent Judong, Aurelie Canivet, Jean-Luc Lorenzo-Villalba, Noel Damas, Pierre |
author_sort | Jadot, Laurent |
collection | PubMed |
description | We report a case of ceftriaxone-induced encephalopathy correlated with a high concentration of the drug in cerebrospinal fluid (CSF). Cephalosporin neurotoxicity is increasingly reported, especially in association with fourth-generation cephalosporins. The factors influencing CSF concentration are plasma concentration, liposolubility, ionization, molecular weight, protein binding and efflux. In our patient, high levels of ceftriaxone (27.9 mg/l) were found in CSF. β-Lactam-associated neurotoxicity is mainly due to similarities between GABA and the β-lactam ring. Because of differences in CSF/plasma ratios and blood–brain barrier efflux among patients, plasma drug monitoring cannot be used to estimate CSF concentration. As far as we know, this is the first reported case of ceftriaxone-induced encephalopathy associated with a high CSF concentration. LEARNING POINTS: Ceftriaxone dose adjustment and clinical surveillance are strongly recommended in patients with renal failure. Measuring ceftriaxone cerebrospinal fluid concentration could be useful for confirming ceftriaxone-induced encephalopathy. |
format | Online Article Text |
id | pubmed-8667992 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | SMC Media Srl |
record_format | MEDLINE/PubMed |
spelling | pubmed-86679922021-12-14 Ceftriaxone-induced Encephalopathy: A Pharmacokinetic Approach Jadot, Laurent Judong, Aurelie Canivet, Jean-Luc Lorenzo-Villalba, Noel Damas, Pierre Eur J Case Rep Intern Med Articles We report a case of ceftriaxone-induced encephalopathy correlated with a high concentration of the drug in cerebrospinal fluid (CSF). Cephalosporin neurotoxicity is increasingly reported, especially in association with fourth-generation cephalosporins. The factors influencing CSF concentration are plasma concentration, liposolubility, ionization, molecular weight, protein binding and efflux. In our patient, high levels of ceftriaxone (27.9 mg/l) were found in CSF. β-Lactam-associated neurotoxicity is mainly due to similarities between GABA and the β-lactam ring. Because of differences in CSF/plasma ratios and blood–brain barrier efflux among patients, plasma drug monitoring cannot be used to estimate CSF concentration. As far as we know, this is the first reported case of ceftriaxone-induced encephalopathy associated with a high CSF concentration. LEARNING POINTS: Ceftriaxone dose adjustment and clinical surveillance are strongly recommended in patients with renal failure. Measuring ceftriaxone cerebrospinal fluid concentration could be useful for confirming ceftriaxone-induced encephalopathy. SMC Media Srl 2021-11-05 /pmc/articles/PMC8667992/ /pubmed/34912745 http://dx.doi.org/10.12890/2021_003011 Text en © EFIM 2021 This article is licensed under a Commons Attribution Non-Commercial 4.0 License |
spellingShingle | Articles Jadot, Laurent Judong, Aurelie Canivet, Jean-Luc Lorenzo-Villalba, Noel Damas, Pierre Ceftriaxone-induced Encephalopathy: A Pharmacokinetic Approach |
title | Ceftriaxone-induced Encephalopathy: A Pharmacokinetic Approach |
title_full | Ceftriaxone-induced Encephalopathy: A Pharmacokinetic Approach |
title_fullStr | Ceftriaxone-induced Encephalopathy: A Pharmacokinetic Approach |
title_full_unstemmed | Ceftriaxone-induced Encephalopathy: A Pharmacokinetic Approach |
title_short | Ceftriaxone-induced Encephalopathy: A Pharmacokinetic Approach |
title_sort | ceftriaxone-induced encephalopathy: a pharmacokinetic approach |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8667992/ https://www.ncbi.nlm.nih.gov/pubmed/34912745 http://dx.doi.org/10.12890/2021_003011 |
work_keys_str_mv | AT jadotlaurent ceftriaxoneinducedencephalopathyapharmacokineticapproach AT judongaurelie ceftriaxoneinducedencephalopathyapharmacokineticapproach AT canivetjeanluc ceftriaxoneinducedencephalopathyapharmacokineticapproach AT lorenzovillalbanoel ceftriaxoneinducedencephalopathyapharmacokineticapproach AT damaspierre ceftriaxoneinducedencephalopathyapharmacokineticapproach |